CytoDyn Invited To Present At XVI World AIDS Conference

SANTA FE, N.M.--(BUSINESS WIRE)--Aug. 4, 2006--CytoDyn, Inc. (OTCBB:CYDY - News) has been invited to present clinical results from Cytolin® at the Treatment Horizons Forum of The AIDS Institute to be held on August 12, 2006 in conjunction with the XVI International AIDS Conference in Toronto. "CytoDyn will show how its targeted immune therapy reduces viral activity while avoiding the emergence of drug-resistant strains of HIV," according to Allen D. Allen, the Company's CEO. The need to continually produce new anti-microbial agents to compensate for the emergence of drug resistant strains of HIV will ultimately be limited by resources, infrastructure, and toxicity, Allen believes.